Metocard

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metocard

What Type of Medicine is Metocard (Metoprolol)?

Metocard is a synthetic, prescription-only medication containing the active ingredient Metoprolol. It is classified as a beta-adrenergic blocking agent (beta-blocker) that acts by blocking the effects of natural stress hormones on the heart and circulatory system. The classification of Metoprolol as a beta-blocker is recognized for its role in cardiovascular management.

Metoprolol is a cardioselective beta-blocker, meaning that at common therapeutic doses, it preferentially targets the beta-1 receptors found mainly in the heart. This feature is a differentiating factor from non-selective agents, establishing its specific application in cardiovascular medicine.


Composition, Forms, and General Therapeutic Purpose

The chemical compound, Metoprolol, is formulated for oral tablet administration using two primary salt forms: Metoprolol Tartrate and Metoprolol Succinate. The Metoprolol Tartrate derivative is generally an immediate-release preparation, absorbed quickly after ingestion. Conversely, the Metoprolol Succinate form is an extended-release preparation, engineered to release the active compound continuously over a 24-hour period. This sustained-release profile allows for once-daily dosing.

The general therapeutic purpose of Metoprolol is to reduce the workload on the heart and promote a stable cardiovascular environment. By decreasing both the heart rate and the force of contraction, the medication helps reduce the heart muscle's overall oxygen demand.

What side effects are possible with Metocard?

Possible Side Effects and Safety Information

The official safety profile for Metoprolol (Metocard) details adverse reactions by frequency and the body system affected, based on regulatory classifications from governmental health authorities. The most frequently documented effects are classified as Common (occurring in 1% to 10% of patients).


Adverse Reaction Scope

Classification Examples of Documented Effects
Common Tiredness, dizziness, bradycardia (slow heart rate), headache, nausea, and diarrhea.
Uncommon to Rare Hypotension, cold extremities, depression, sleep disturbances, confusion, and temporary memory loss.

System-Organ Classes and Serious Reactions

Adverse reactions are grouped into System-Organ Classes (SOCs), which include Central Nervous System, Cardiovascular, and Gastrointestinal Disorders. The prescribing information documents the potential for serious adverse reactions, which are typically rare or very rare post-marketing events. These include heart block, hepatitis, and the aggravation of psoriasis.


Safety Considerations and Restrictions

Safety statements exist for specific patient groups. For example, hepatic impairment may reduce drug clearance, potentially requiring consideration of a lower dosage. Metoprolol may also mask the symptoms of hypoglycemia, such as tachycardia, in diabetic patients. Contraindications formally prohibit use in patients with conditions such as severe bradycardia, second- or third-degree heart block, cardiogenic shock, and severe decompensated heart failure. Additionally, a withdrawal phenomenon is noted, where abrupt cessation of therapy has been associated with an exacerbation of cardiac symptoms.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information details the officially documented manifestations and required emergency actions for a Metocard (Metoprolol) overdose, strictly based on government regulatory documentation.


Documented Overdose Manifestations

System Documented Clinical Presentations
Cardiovascular Severe bradycardia, profound hypotension, second- or third-degree heart block, heart failure, and cardiac arrest are documented risks.
CNS & Respiratory Drowsiness, confusion, coma, convulsions, and bronchospasm (breathing difficulty) are associated findings.

Required Emergency Actions

Overdose is classified as having the potential for life-threatening outcomes and requires immediate attention. Regulatory guidance states that individuals must seek medical help right away and call emergency services or a Poison Control center immediately upon suspicion of overdose. In the event of an overdose, management is symptomatic and supportive, as no specific antidote is identified in the official labeling. Procedures described in the regulatory texts include gastric lavage, administration of activated charcoal, and the use of specific agents like atropine or vasopressors to manage critical symptoms. Hospital monitoring, including continuous ECG observation, is required, particularly with extended-release formulations due to the potential for delayed toxicity. Low blood sugar (hypoglycemia) is a specific concern documented in pediatric cases.

Therapeutic Uses of Metocard

What Metocard Treats: Main Uses and Benefits

Metocard (Metoprolol) is a foundational medication used across multiple clinical domains to provide essential long-term support by easing physiological strain and managing recurrent symptom patterns. It is primarily used when symptoms create noticeable interference with daily stability due to heightened vascular or cardiac activity. Its main therapeutic purposes generally include treating high blood pressure, chronic angina, and providing vital support in post-heart attack management. It is also commonly used for stabilizing rapid heart rhythms and for the prophylactic management of recurrent migraine headaches.


Managing Symptom Clusters

The medication is generally applied in contexts marked by increased discomfort or tension, supporting the patient during episodes of heightened discomfort. In these situations, Metocard assists with maintaining functional stability by addressing symptoms that interfere with daily functioning.

“The therapeutic approach is to ease the overall symptom burden and support efforts toward maintaining functional stability during periods of heightened physiological activity.”


Quick Fact: Support for Vascular and Heart Rate Strain Symptoms

Quick Fact: Support for Vascular and Heart Rate Strain Symptoms

Metocard is considered relevant for managing symptoms related to sustained hypertension and effort-induced chest discomfort. It also plays a role in managing symptoms of rapid heart rate (tachycardia) and recurrent, intense headache patterns, contributing to improved comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for Metocard (Metoprolol) is strictly defined by government regulatory documents, focusing on existing cardiac function, age, and comorbid conditions.

Contraindications (Must Not Use)

Metocard is formally contraindicated in patients with the following conditions:

  • Severe Bradycardia (very slow heart rate, typically le 50 beats/min).
  • Cardiogenic Shock or Decompensated Heart Failure.
  • High-Degree Heart Block (Second- or Third-Degree AV Block) or Sick Sinus Syndrome, unless a functioning pacemaker is present.
  • Severe Hypotension (low blood pressure) or known Hypersensitivity to Metoprolol or other beta-blockers.

Established and Conditional Use

Population Group Regulatory Status and Constraint
Adults Established use for all labeled indications.
Pediatric Patients Established use for the extended-release formulation in children aged ge 6 years for Hypertension. Safety/efficacy not established for children <6 years.
Hepatic Impairment Caution is required; a lower starting dose may be necessary due to the liver's role in drug metabolism.
Renal Impairment No dose adjustment is usually needed as kidney function does not significantly alter elimination.
Pregnancy/Lactation Use in pregnancy is conditional (only if clearly needed). Minimal risk is reported during lactation.

Official labels also caution use in patients with Diabetes Mellitus (may mask low blood sugar signs) and Bronchospastic Disease (e.g., severe asthma) due to potential for exacerbation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Metocard (Metoprolol) has officially documented interaction patterns classified primarily based on their effects on the drug’s concentration or its physiological action.

The most significant are pharmacokinetic interactions, driven by the hepatic CYP2D6 enzyme pathway. Co-administration with strong CYP2D6 inhibitors, such as fluoxetine or quinidine, is documented to increase metoprolol plasma concentrations, potentially leading to greater exposure. Conversely, hepatic enzyme inducers, such as rifampicin, may reduce metoprolol concentrations. This metabolic interaction is a factor for individuals classified as CYP2D6 Poor Metabolizers, who exhibit several-fold higher plasma concentrations. Regulatory caution is also noted regarding interaction severity in patients with hepatic impairment.

Pharmacodynamic interactions involve additive effects, primarily when Metocard is co-administered with other heart rate- or blood pressure-lowering agents. This includes substances like verapamil or digitalis glycosides, which carry an officially documented risk of marked bradycardia or hypotension.

A specific timing-based restriction applies when discontinuing combination therapy with clonidine: Metoprolol must be withdrawn several days before clonidine to mitigate the risk of rebound hypertension. The official label notes that alcohol interferes with the extended-release succinate formulation, and that Metoprolol may impair the elimination of co-administered drugs like lignocaine.

Mechanism of Action

How Metocard Works

The mechanism of Metoprolol is centered on reducing signals mediated by the sympathetic nervous system, which results in lowered cardiac function.

Blockade of Cardiac beta1 Receptors

Metoprolol functions as a competitive antagonist that primarily targets the beta1-adrenergic receptors found on heart muscle and electrical conduction tissue. By blocking these receptors, the drug prevents the powerful stimulating effects of the body's stress hormones (catecholamines), thereby interrupting the internal signaling cascades (cAMP/PKA). This molecular action results in two physiological consequences: a negative chronotropic effect (decreased heart rate) and a negative inotropic effect (decreased force of contraction).

Modulation of Systemic Regulatory Pathways

Beyond its direct effects on the heart, Metoprolol's beta1 blockade extends to the kidneys, where it suppresses the release of the enzyme renin. Renin is the initial step in the Renin-Angiotensin System (RAS), a key hormonal pathway involved in regulating fluid volume and vascular tone. This mechanism results in an alteration of the pathway's contribution to circulatory and systemic pressure maintenance.

Mechanistic Limitations (Loss of Selectivity)

The drug's primary interaction with beta1 receptors holds true only at typical plasma concentrations. When higher concentrations occur (e.g., due to impaired metabolism), the mechanism's specificity is lessened, and Metoprolol begins to interact with beta2-adrenergic receptors found in other tissues. This shift in receptor engagement expands the drug's activity to pathways that modulate peripheral smooth muscle tone.

Dosage and Administration Information

Official Administration Guidelines for Metocard (Metoprolol)

The use of Metoprolol is governed by administration protocols that depend on the specific formulation being used: immediate-release (IR) Metoprolol Tartrate or extended-release (ER) Metoprolol Succinate. The IR tablets are generally administered in divided doses throughout the day, while the ER form is typically taken once daily. The medication is primarily for oral administration, though an intravenous (IV) form is approved for acute treatment in highly monitored settings, such as post-myocardial infarction care.

Dosing and Administration Conditions

Administration Aspect Official Instruction Summary
Timing & Food IR tablets must be taken with or immediately following food/meals for proper absorption. ER forms may be taken with or without food.
Dose Titration Dosage adjustments for chronic conditions must be made gradually, typically at intervals of one week or longer, until the required maintenance range is reached.
Standard Dose Range Adult maintenance doses for hypertension and angina generally fall between 100 mg and 400 mg daily, depending on the formulation and indication.

Procedural Constraints

For the extended-release formulation, it is a strict procedural constraint that the tablets or pellets must not be crushed or chewed to avoid compromising the controlled-release mechanism. If a dose is missed, instructions state that the user should take only the next regularly scheduled dose and should not double the dose. Furthermore, chronic use of Metoprolol should never be stopped abruptly; instead, the dosage must be gradually reduced over a period of one to two weeks before complete cessation. This gradual tapering is a protocol designed to manage the physiological response to withdrawal.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Metocard (Metoprolol)


Evidence for Use in Managing High Blood Pressure

Metocard was studied for its use in high blood pressure (hypertension) through numerous Randomized Controlled Trials (RCTs) and large-scale studies. Research has examined the effect of the medication by measuring changes in systolic and diastolic blood pressure readings over defined time intervals. Long-term studies monitored patient groups to report on patterns of major cardiovascular events, such as stroke, in those receiving metoprolol. The immediate-release formulation was observed in some studies to have fluctuating blood pressure measurements over a full 24-hour period.

Evidence for Use After a Heart Attack

Large-scale, long-term RCTs was studied for its use following a heart attack (myocardial infarction). Research examined all-cause mortality, the rate of cardiovascular death, and the risk of experiencing a recurrent heart attack (reinfarction). Landmark trials reported measurements of long-term mortality patterns in observed populations, particularly in research conducted before modern emergency treatments like stenting became standard. Research describes patterns related to reinfarction that appear to correlate with the patient's existing heart function.

Key Uncertainty: Recent research in patients with preserved left ventricular ejection fraction (LVEF) following a heart attack suggests that the benefit seen in older trials for major cardiovascular events may not be fully established in the modern treatment environment.


Evidence for Use in Chronic Heart Failure

Major placebo-controlled RCTs was observed in patients with chronic, stable heart failure where the heart’s pumping function is reduced. These trials exclusively studied the extended-release succinate formulation alongside standard treatments. Research examined total mortality, the frequency of hospitalizations due to heart failure symptoms, and changes in the patient's daily functioning or activity level. The research base was centered on the extended-release succinate salt form, and data for certain groups remain insufficient for the immediate-release tartrate form in this indication.

Research Gaps and Limitations

Key limitations in the research include the fact that many of the core studies are historical, meaning comparative evidence against the newest available treatments is often lacking. For conditions like hypertension and angina, the long-term patterns related to major cardiovascular events are not fully established when compared to some alternative medication classes. Research in areas such as migraine prevention and managing rapid heart rhythms often relied on smaller sample sizes than the studies for heart failure. The research contributes to understanding symptom patterns—and what is still uncertain, and does not determine whether an individual will respond similarly to the group patterns observed in the trials.

Key Studies & References

  1. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.
  2. Long-Term Effect of $beta$-Blocker Use on Clinical Outcomes in Postmyocardial Infarction Patients: A Systematic Review and Meta-Analysis
  3. Metoprolol: MedlinePlus Drug Information (Authoritative overview used for indications and general context)

Frequently Asked Questions (FAQ)

Common questions about Metocard (FAQ)


Q: Does Metocard cause weight gain, and is that a common concern among users?

Official product information states that weight gain is reported as an uncommon side effect, affecting less than 1% of patients in clinical trials. However, sudden or substantial weight gain may also be a sign of fluid retention, which is a safety consideration for cardiac conditions. If unexpected weight changes occur, this is a development often reviewed by a healthcare provider.

Q: Does the food I eat (like grapefruit or potassium-rich foods) interact with Metocard?

Official guidance generally indicates that patients can eat and drink normally while taking this medication. The exception is the immediate-release tablet, which is directed to be taken with or immediately following food to ensure proper absorption. No specific restriction on foods like grapefruit or high-potassium items is noted in the official regulatory labeling.

Q: Does taking Metocard affect fertility or sexual function (like sex drive or erectile dysfunction)?

Regulatory safety information documents that sexual dysfunction or impotence is a rare side effect of Metoprolol. Decreased interest in sexual activity or disturbances of libido have also been reported rarely. These effects are classified within the uncommon to rare categories of adverse reactions.

Q: Can Metocard cause a slow heart rate (bradycardia), and what rate is considered too low?

Metoprolol commonly causes a slowing of the heart rate (bradycardia) as part of its intended mechanism. Official safety information specifies that a resting heart rate persistently below 50 to 55 beats per minute is a regulatory threshold where medical professionals would consider reducing the dosage or stopping the medication. This is a point of clinical caution noted in the product labeling.

Q: Is the dizziness or lightheadedness from Metocard more common when first starting the medication?

According to official patient medication guides, side effects such as dizziness, light-headedness, or feeling sluggish are typically more common when treatment is first initiated or following a dosage increase. These symptoms often tend to improve as the body adjusts to the medication.

Q: If Metocard is taken for palpitations, how long should it take to control the irregular heart rhythm?

The medication's effect on heart rhythm may begin within an hour of administration, as its active components start to affect heart function. However, it is observed that consistent control of symptoms may be seen after 1 to 2 weeks of continuous dosing.

Q: Is the tiredness or fatigue from Metocard temporary, or does it last as long as I take the medicine?

Tiredness or fatigue is listed as a common side effect in the official safety profile. This effect often tends to lessen or improve over time as the body adapts to the medication's mechanism of action.

Q: How long does it usually take to fully start working after starting treatment?

The medication begins to work by lowering the heart rate within about an hour of taking the tablet. However, it is observed that the full blood pressure-lowering or anti-anginal effect may be reached after 1 to 2 weeks of use.

Q: Is it common to not feel any different even if Metocard is working correctly?

Yes, it is a common expectation that patients may not notice any immediate physical change or subjective feeling when taking Metoprolol, especially when it is prescribed for blood pressure management. The absence of feeling different does not indicate that the medication is not working, as its effects are typically measured physiologically and may not lead to subjective changes.

Q: Can Metocard affect my ability to drive or safely operate machinery?

Official warnings describe that individuals are advised not to drive a car or operate machinery until they determine how the medication affects them, due to the potential risk of dizziness, drowsiness, or decreased alertness.

Q: Are there any reported long-term side effects associated with taking Metocard for many years?

The regulatory safety profile lists all known adverse reactions by frequency (e.g., Common, Rare) based on all clinical experience. Metoprolol is a medication that is often taken for many years, but the overall safety data is grouped together, rather than separating out a distinct category of side effects unique to long-term use.

Q: Does Metocard interact with common pain relievers or over-the-counter medicines?

Co-administration with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen, is documented in the drug interaction sections of the official label. Long-term use of NSAIDs may reduce Metoprolol's blood pressure-lowering effect, and official labeling notes that caution and monitoring may be warranted.

Q: Does Metocard affect cholesterol or triglyceride levels in the body?

Some regulatory safety data reports metabolic effects, including increased blood triglycerides and decreased HDL ('good cholesterol'). The incidence of these changes is not always fully established but is noted in post-marketing or clinical reports.

Q: Why is Metocard sometimes used to prevent migraines?

Metoprolol is recognized and used to help prevent headaches in patients who experience migraines. It is cited in clinical guidelines as an effective agent for prevention, based on research evidence.

Q: Do I need to inform a surgeon or dentist that I am taking Metocard before an operation?

Official warnings describe that patients are advised to inform their surgeon, anesthesiologist, or dentist that they are taking Metoprolol if they are undergoing any type of surgery, including dental procedures. This precaution is noted in the warnings section related to perioperative use.

Q: Is it necessary to have regular blood tests or check-ups while taking Metocard long-term?

Official monitoring guidelines state that healthcare providers typically monitor heart rate and rhythm regularly while the patient is on Metoprolol. Additionally, individuals with diabetes may need to check their blood sugar more frequently, as the drug can potentially mask typical symptoms of low blood sugar.

Q: What should I look out for as signs of a possible allergic reaction to Metocard?

Signs of a possible severe reaction are documented in the serious adverse reaction sections of the prescribing information. These symptoms include swelling of the hands, feet, ankles, or lower legs, shortness of breath, wheezing, or significant skin reactions such as hives or welts. If any of these serious reactions occur, the patient is officially advised to seek immediate medical attention.

Q: Does Metocard affect the thyroid gland or mask symptoms of an overactive thyroid (hyperthyroidism)?

Beta-blockers may mask certain physical signs of an overactive thyroid (hyperthyroidism). Furthermore, official warnings note that they can affect hormone metabolism, potentially leading to elevated serum free thyroxine (T4) levels. This is a safety consideration documented in the prescribing information.

Q: Are there any lifestyle or diet changes that can make Metocard work better?

Official guidance often describes complementary lifestyle and diet changes that may support the medication's therapeutic goals. These recommendations include quitting smoking, regular exercise, reducing alcohol intake, and maintaining a healthy, low-salt diet for overall cardiovascular health.

How should Metocard be stored and disposed of?

Storage and Disposal Requirements for Metocard (Metoprolol)

The medicine must be stored at Controlled Room Temperature, which is typically 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C (86 F). Metocard must be kept in a tight, light-resistant container and protected from excessive heat and freezing to maintain stability. For safety, the product must be stored out of the reach of children.


Disposal

Disposal of unused or expired Metocard should prioritize a community drug take-back program. If this option is unavailable, the medication should be mixed with an undesirable substance (such as used coffee grounds) and sealed in a container before being thrown in the household trash. Metoprolol is not to be flushed down the toilet or poured down the sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metocard found in:

A-Z Index: